StreetAlpha.app
Home › Stocks › INCY

Incyte Corp (INCY)

Healthcare
$119.09
▼ −0.98%
LAST CLOSE · NOV 17

Incyte develops and sells prescription medicines, mainly for blood cancers and other conditions. It last closed at $119.09 on Nov 17, down 0.98% on the day. INCY reports earnings on Tue, Feb 9, 2027. The average 12-month price target from 13 analysts is $135.00 (+13.4% from the last close), with a high of $157.00 and a low of $108.00. Analyst consensus is Buy, based on the latest ratings from 13 firms (7 buy, 6 hold, 0 sell). Over the past 90 days StreetAlpha recorded 2 whale options trades in INCY, 0% of them bullish and 100% bearish. In the past 30 days there were 3 dark pool prints totaling $2.5M, the largest $1.1M.

AI Auto Pilots
Is INCY in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$6.0B
+24.9% vs a year ago
Net income
$403.4M
−66.1% vs a year ago
EPS (diluted)
$1.96
−66.8% vs a year ago
Gross margin
92.7%
$5.6B gross profit
Valuation
Market cap
$24.3B
203.8M shares
P/E
60.8
Price over 12 month EPS
Price to sales
4.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$3.3B
At Sep 30
Shareholder equity
$5.6B
Shares outstanding
203.8M
At Oct 22
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.0B$3.0BFY2021FY2022: $3.4B$3.4BFY2022FY2023: $3.7B$3.7BFY2023FY2024: $4.2B$4.2BFY2024FY2025: $5.1B$5.1BFY2025

From INCY's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
Feb 9
2027 · Time not announced
Consensus EPS forecast
$1.90
$1.56B revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Buy
Based on 13 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Buy
13firms
7 Buy6 Hold0 Sell
Each firm's latest rating on INCY in the past 90 days
Average 12-month target
$135.00
▲ 13.4% upside

Based on 13 analysts who set a price target on INCY in the past 90 days. The average target is $135.00, with a high of $157.00 and a low of $108.00, compared with the last close of $119.09.

Low $108.00Avg $135.00High $157.00
Blue marker: last close $119.09
Highest target$157.00
Average target$135.00
Lowest target$108.00
Latest rating changes
Leerink PartnersTarget lowered
Nov 5Buy$155 → $150
BernsteinTarget raised
Nov 2Hold$99 → $108
Wells FargoTarget lowered
Oct 30Hold$128 → $127
RBC CapitalTarget raised
Oct 30Hold$114 → $117
BarclaysTarget raised
Oct 30Buy$139 → $143
DateFirmActionRatingPrice target
Nov 5Leerink PartnersTarget loweredBuy$155 → $150
Nov 2BernsteinTarget raisedHold$99 → $108
Oct 30Wells FargoTarget loweredHold$128 → $127
Oct 30RBC CapitalTarget raisedHold$114 → $117
Oct 30BarclaysTarget raisedBuy$139 → $143
Loading…

Technical Analysis

INCY · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 0% above its 20 day and 0% above its 50 day average. It is 8% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 50). The nearest support is the 50 day average at $118.94, and the nearest resistance the Pivot at $119.52.

Short trendNeutral
Long trendBullish
MomentumImproving
StretchNormal
VolatilityHigh, 3.2%/day
Key levels
$132.6052 week high+11.3%
$121.00Pivot R1+1.6%
$119.98100 day average+0.7%
$119.60Swing high (Jul 17)+0.4%
$119.52Pivot+0.4%
$119.09Last close
$118.9450 day average−0.1%
$118.7320 day average−0.3%
$117.62Pivot S1−1.2%
$117.56Swing low (Aug 14)−1.3%
$109.10200 day average−8.4%
$89.2552 week low−25.1%
Indicators
RSI (14)50.29Middle of its rangeNeutral
MACD0.91Above its signal lineBullish
Stochastic70.3Middle of its rangeNeutral
ADX (14)11.3No clear trend
Williams %R-37.6Oversold below −80, overbought above −20Neutral
CCI (20)27.4Oversold below −100, overbought above 100Neutral
Rate of change+1.3%Change over 10 sessionsBullish
ATR (14)$3.76Typical daily range, 3.2% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Below
MA 200Above
What happened before, for INCY

What happened before

See how INCY did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow INCY usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How INCY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
2
Bullish
0
0%
Bearish
2
100%
Date span
Sep 18 – Oct 13
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
3
Notional
$2.5M
Largest print
$1.1M
Loading…

INCY Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲499 buying vs 351 selling
  • ▼Held by funds -2.1 pts
  • ▲Funds holding +37
  • ▼Superinvestors: 1 added, 3 cut
  • ▼Put/call 0.75 to 4.28
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding899862+4.3%
In funds' top 101113−15.4%
Held by funds97.9%100.0%−2.1 pts
New / increased134 / 365117 / 358+5.1%
Reduced / sold out270 / 81272 / 75+1.2%
Put/call ratio4.280.75+469.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See INCY institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

INCY Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
—
 
Left in program
—
 
Shares outstanding, 12 months
+3.8%
More shares
Last quarter
—
Sep 2026
Avg price paid, last quarter
—
 
S&P 500 rank by spending
—
 
Spent each quarter, last 3 yearsTop bar $2.0B
Dec 2023: $0Mar 2024: $0Jun 2024: $2.0B, average price $60.00Sep 2024: $0Dec 2024: $0Mar 2025: $0Jun 2025: $0Sep 2025: $0Dec 2025: $0Mar 2026: $0Jun 2026: $0Sep 2026: $0
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Oct 29, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INCY is in one of them and how their past INCY trades turned out.

INCY in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered INCY in an article yet. Here's the latest on the wider market.

INCY Congress Trades

All congress trades →
Trades, 12 months
4
Buys
3
75%
Sells
1
25%
People
1
Last filed Nov 5
Who traded INCY · since 2017
Latest 5 filings of 26
$1K – $15KTraded Oct 7, 2026Filed Nov 5, 2026
$1K – $15KTraded Sep 4, 2026Filed Oct 7, 2026
$1K – $15KTraded May 15, 2026Filed Jun 9, 2026
$1K – $15KTraded Jan 29, 2026Filed Feb 6, 2026
$1K – $15KTraded May 19, 2025Filed Jun 12, 2025
PersonTypeAmountTradedFiledDelay
Ro KhannaD · CASell$1K – $15KOct 7, 2026Nov 5, 202629 d
Ro KhannaD · CABuy$1K – $15KSep 4, 2026Oct 7, 202633 d
Ro KhannaD · CABuy$1K – $15KMay 15, 2026Jun 9, 202625 d
Ro KhannaD · CABuy$1K – $15KJan 29, 2026Feb 6, 20268 d
Ro KhannaD · CABuy$1K – $15KMay 19, 2025Jun 12, 202524 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Incyte

Incyte is a biopharmaceutical company based in Wilmington, Delaware. It discovers, develops and sells prescription medicines, mainly for blood cancers and other conditions, including a topical cream. Physicians prescribe its products to patients, and insurers and other payors decide on coverage. Some of its products are also developed and sold with partners, including Novartis and Lilly.

Headquarters
Wilmington, DE
Founded
2001